To clarify these issues, we herein show the continuous reduction of TSP2 levels by DAA treatment and demonstrate the utility of TSP2 as a predictive marker for HCC development after DAA therapy among hepatitis C patients with and without prior HCC. This evidence concerns the gene THBS2 and hepatocellular carcinoma.